Cerebral Amyloid and Hypertension are Independently Associated with White Matter Lesions in Elderly

In cognitively normal (CN) elderly individuals, white matter hyperintensities (WMH) are commonly viewed as a marker of cerebral small vessel disease (SVD). SVD is due to exposure to systemic vascular injury processes associated with highly prevalent vascular risk factors (VRFs) such as hypertension, high cholesterol, and diabetes. However, cerebral amyloid accumulation is also prevalent in this population and is associated with WMH accrual. Therefore, we examined the independent associations of amyloid burden and VRFs with WMH burden in CN elderly individuals with low to moderate vascular risk. Participants (n = 150) in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) received fluid attenuated inversion recovery (FLAIR) MRI at study entry. Total WMH volume was calculated from FLAIR images co-registered with structural MRI. Amyloid burden was determined by cerebrospinal fluid Aβ1-42 levels. Clinical histories of VRFs, as well as current measurements of vascular status, were recorded during a baseline clinical evaluation. We tested ridge regression models for independent associations and interactions of elevated blood pressure (BP) and amyloid to total WMH volume. We found that greater amyloid burden and a clinical history of hypertension were independently associated with greater WMH volume. In addition, elevated BP modified the association between amyloid and WMH, such that those with either current or past evidence of elevated BP had greater WMH volumes at a given burden of amyloid. These findings are consistent with the hypothesis that cerebral amyloid accumulation and VRFs are independently associated with clinically latent white matter damage represented by WMHs. The potential contribution of amyloid to WMHs should be further explored, even among elderly individuals without cognitive impairment and with limited VRF exposure.

[1]  Carole Dufouil,et al.  Antihypertensive Treatment and Change in Blood Pressure Are Associated With the Progression of White Matter Lesion Volumes: The Three-City (3C)–Dijon Magnetic Resonance Imaging Study , 2011, Circulation.

[2]  Klaus P. Ebmeier,et al.  Lifetime hypertension as a predictor of brain structure in older adults: cohort study with a 28-year follow-up , 2015, British Journal of Psychiatry.

[3]  C. DeCarli,et al.  Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline , 2011, Alzheimer's & Dementia.

[4]  J. Schneider,et al.  Vascular contributions to cognitive impairment and dementia including Alzheimer's disease , 2015, Alzheimer's & Dementia.

[5]  F. Fazekas,et al.  Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. , 1996, Stroke.

[6]  P. Wolf,et al.  Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. , 2009, Stroke.

[7]  Vijay K. Venkatraman,et al.  Longitudinal Systolic Blood Pressure Characteristics and Integrity of White Matter Tracts in a Cohort of Very Old Black and White Adults , 2014, American Journal of Hypertension.

[8]  A. Joutel,et al.  Early white matter changes in CADASIL: evidence of segmental intramyelinic oedema in a pre-clinical mouse model , 2014, Acta neuropathologica communications.

[9]  Wiro J Niessen,et al.  High Blood Pressure and Cerebral White Matter Lesion Progression in the General Population , 2013, Hypertension.

[10]  B. Mazoyer,et al.  Plasma &bgr;-amyloid and MRI markers of cerebral small vessel disease: Three-City Dijon Study , 2014, Neurology.

[11]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[12]  A. Hofman,et al.  Determinants, MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam Study. , 2014, Journal of Alzheimer's disease : JAD.

[13]  M. Mintun,et al.  Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.

[14]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[15]  M. Woodward,et al.  Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy , 2005, Circulation.

[16]  R. Sacco,et al.  Lipid Profile Components and Subclinical Cerebrovascular Disease in the Northern Manhattan Study , 2014, Cerebrovascular Diseases.

[17]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[18]  P. Scheltens,et al.  Dementia: Alzheimer pathology and vascular factors: from mutually exclusive to interaction. , 2012, Biochimica et biophysica acta.

[19]  M. Carrillo,et al.  Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective , 2015, Alzheimer's & Dementia.

[20]  A Hofman,et al.  Cerebral white matter lesions and atherosclerosis in the Rotterdam Study , 1993, The Lancet.

[21]  Owen Carmichael,et al.  Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. , 2013, Psychology and aging.

[22]  Owen Carmichael,et al.  Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. , 2010, Archives of neurology.

[23]  Robert A. Dean,et al.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.

[24]  A. Brickman Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities , 2013, Current Neurology and Neuroscience Reports.

[25]  O. Levin,et al.  [Cerebral amyloid angiopathy]. , 2014, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[26]  W. M. van der Flier,et al.  Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[28]  J. Meulman,et al.  Prediction accuracy and stability of regression optimal scaling transformations , 1996 .

[29]  W. W. Muir,et al.  Regression Diagnostics: Identifying Influential Data and Sources of Collinearity , 1980 .

[30]  W. Jagust,et al.  Vascular burden and Alzheimer disease pathologic progression , 2012, Neurology.

[31]  A Hofman,et al.  A follow‐up study of blood pressure and cerebral white matter lesions , 1999, Annals of neurology.

[32]  L. Launer,et al.  Lowering Midlife Levels of Systolic Blood Pressure as a Public Health Strategy to Reduce Late-Life Dementia: Perspective From the Honolulu Heart Program/Honolulu Asia Aging Study , 2010, Hypertension.

[33]  Nick C. Fox,et al.  Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls , 2013, Neurobiology of Aging.

[34]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[35]  J. Becker,et al.  Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[36]  G. Biessels,et al.  Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. , 2015, The lancet. Diabetes & endocrinology.

[37]  S. D. Preston,et al.  Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain , 2003, Neuropathology and applied neurobiology.

[38]  A. Wallin,et al.  Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42 , 2006, Neurology.

[39]  M. Mullan,et al.  β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.

[40]  Masanori Ichise,et al.  Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated , 2015, Neuroscience Letters.

[41]  Thaddeus J. Haight,et al.  Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. , 2013, JAMA neurology.

[42]  OphéliaGodin,et al.  Antihypertensive Treatment and Change in Blood Pressure Are Associated With the Progression of White Matter Lesion Volumes , 2011 .

[43]  Sandra Black,et al.  Understanding White Matter Disease: Imaging-Pathological Correlations in Vascular Cognitive Impairment , 2009, Stroke.

[44]  Owen T. Carmichael,et al.  White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment , 2013, Alzheimer's & Dementia.

[45]  C. DeCarli,et al.  Association of midlife blood pressure to late-life cognitive decline and brain morphology , 1998, Neurology.

[46]  Jordan Muraskin,et al.  White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? , 2013, JAMA neurology.

[47]  M. Mullan,et al.  beta-Amyloid-mediated vasoactivity and vascular endothelial damage. , 1996, Nature.

[48]  D. Harvey,et al.  Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD , 2006, Neurology.

[49]  C. Wright,et al.  Vascular contributions to cognitive impairment. , 2015, Neurology. Clinical practice.